Major Depressive Disorder Following Dermatomyositis: A Case Linking Depression with Inflammation

Overview

Journal Psychopharmacol Bull

Specialty Pharmacology

Date 2018 May 2

PMID 29713102

Citations 1

Authors

Abhishek Reddy

Badari Birur

Richard C Shelton

Li Li

Affiliations

Soon will be listed here.

Abstract

Major depressive disorder (MDD) is one of the most common psychiatric disorders. Recent studies have shown a strong association between MDD and peripheral inflammation, shown by a higher incidence of depression in patients with inflammatory diseases including rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis and systemic lupus erythematosus. Dermatomyositis (DM), an idiopathic inflammatory connective tissue disease that is associated with inflammation, predominantly affects the skin and skeletal muscle. The association between DM and MDD in the context of inflammation has seldom been reported. Here we report a 30- year- old Caucasian female with symptoms of depression dating back to 2 years. These symptoms started after cutaneous manifestations of DM. In the past two years, her DM symptoms have worsened that paralleled an increase of depressive symptoms. Also, during the course of the patient's DM, we tracked elevated inflammatory markers including creatine kinase and aldolase, whereas C-reactive protein, C3, and C4 were in a high normal range which correlated with worsening of depression. Hence, a temporal relationship between the onset of MDD and DM symptoms suggests that inflammation may be a common mechanism linking these two conditions.

Citing Articles

Antidepressant-Like Effect of in Mice Exposed to a Chronic Mild Stress Involves the microRNA-298-5p-Mediated Nox1.

Zou T, Zhang J, Liu Y, Zhang Y, Sugimoto K, Mei C Front Mol Neurosci. 2021; 13:131.

PMID: 33613190 PMC: 7886707. DOI: 10.3389/fnmol.2020.00131.

References

Kessler R, Berglund P, Demler O, Jin R, Merikangas K, Walters E . Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005; 62(6):593-602. DOI: 10.1001/archpsyc.62.6.593. View

Maes M, Bosmans E, De Jongh R, Kenis G, Vandoolaeghe E, Neels H . Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine. 1998; 9(11):853-8. DOI: 10.1006/cyto.1997.0238. View

Tymms K, Webb J . Dermatopolymyositis and other connective tissue diseases: a review of 105 cases. J Rheumatol. 1985; 12(6):1140-8. View

Dickens C, McGowan L, Clark-Carter D, Creed F . Depression in rheumatoid arthritis: a systematic review of the literature with meta-analysis. Psychosom Med. 2002; 64(1):52-60. DOI: 10.1097/00006842-200201000-00008. View

Kraus M, Schafer A, Schottker K, Keicher C, Weissbrich B, Hofbauer I . Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study. Gut. 2007; 57(4):531-6. DOI: 10.1136/gut.2007.131607. View

Dalakas M, Hohlfeld R . Polymyositis and dermatomyositis. Lancet. 2003; 362(9388):971-82. DOI: 10.1016/S0140-6736(03)14368-1. View

Howren M, Lamkin D, Suls J . Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med. 2009; 71(2):171-86. DOI: 10.1097/PSY.0b013e3181907c1b. View

Raison C, Rutherford R, Woolwine B, Shuo C, Schettler P, Drake D . A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry. 2012; 70(1):31-41. PMC: 4015348. DOI: 10.1001/2013.jamapsychiatry.4. View

Dahl J, Ormstad H, Aass H, Malt U, Traskman Bendz L, Sandvik L . The plasma levels of various cytokines are increased during ongoing depression and are reduced to normal levels after recovery. Psychoneuroendocrinology. 2014; 45:77-86. DOI: 10.1016/j.psyneuen.2014.03.019. View

10.

Capuron L, Fornwalt F, Knight B, Harvey P, Ninan P, Miller A . Does cytokine-induced depression differ from idiopathic major depression in medically healthy individuals?. J Affect Disord. 2009; 119(1-3):181-5. PMC: 2763953. DOI: 10.1016/j.jad.2009.02.017. View

11.

Achtman J, Kling M, Feng R, Okawa J, Werth V . A cross-sectional study of untreated depression and anxiety in cutaneous lupus erythematosus and dermatomyositis. J Am Acad Dermatol. 2016; 74(2):377-9. PMC: 4878998. DOI: 10.1016/j.jaad.2015.09.016. View

12.

Setiawan E, Wilson A, Mizrahi R, Rusjan P, Miler L, Rajkowska G . Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes. JAMA Psychiatry. 2015; 72(3):268-75. PMC: 4836849. DOI: 10.1001/jamapsychiatry.2014.2427. View

13.

Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A . Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet. 2006; 367(9504):29-35. DOI: 10.1016/S0140-6736(05)67763-X. View

14.

Ramanan A, Sawhney S, Murray K . Central nervous system complications in two cases of juvenile onset dermatomyositis. Rheumatology (Oxford). 2001; 40(11):1293-8. DOI: 10.1093/rheumatology/40.11.1293. View

15.

Bohan A, Peter J, Bowman R, Pearson C . Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine (Baltimore). 1977; 56(4):255-86. DOI: 10.1097/00005792-197707000-00001. View

16.

Raison C, Capuron L, Miller A . Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2005; 27(1):24-31. PMC: 3392963. DOI: 10.1016/j.it.2005.11.006. View

17.

Lo Fermo S, Barone R, Patti F, Laisa P, Cavallaro T, Nicoletti A . Outcome of psychiatric symptoms presenting at onset of multiple sclerosis: a retrospective study. Mult Scler. 2010; 16(6):742-8. DOI: 10.1177/1352458510365157. View

18.

Musselman D, Lawson D, Gumnick J, Manatunga A, Penna S, Goodkin R . Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med. 2001; 344(13):961-6. DOI: 10.1056/NEJM200103293441303. View

19.

Graff L, Walker J, Bernstein C . Depression and anxiety in inflammatory bowel disease: a review of comorbidity and management. Inflamm Bowel Dis. 2009; 15(7):1105-18. DOI: 10.1002/ibd.20873. View

20.

Maes M, Kubera M, Obuchowiczwa E, Goehler L, Brzeszcz J . Depression's multiple comorbidities explained by (neuro)inflammatory and oxidative & nitrosative stress pathways. Neuro Endocrinol Lett. 2011; 32(1):7-24. View